Raltitrexed
Top View
- NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2010
- Biweekly Oxaliplatin, Raltitrexed, 5-Fluorouracil and Folinic Acid Combination Chemotherapy During Preoperative Radiation Therap
- Electronic Supplementary Material (ESI) for Lab on a Chip. This Journal Is © the Royal Society of Chemistry 2020
- 2012 NIOSH List of Antineoplastic and Other Hazardous Drugs
- Induces Thymineless Death with Topoisomerase I-DNA Complexes
- Activity and Toxicity of Oxaliplatin Plus Raltitrexed in 5-Fluorouracil Refractory Metastatic Colorectal Adeno-Carcinoma
- Pre-Operative Radiochemotherapy with Raltitrexed for Resectable Locally-Advanced Rectal Cancer: a Phase II Study*
- Formulation of Folate-Modified Raltitrexed-Loaded Nanoparticles
- Hair Loss and Chemotherapy
- MANUAL for Medical Facilities
- Cytochrome P450 1B1 Gene Polymorphisms As Predictors of Anticancer Drug Activity: Studies with in Vitro Models
- Management of Extravasation of a Systemic Anti-Cancer Therapy Including Cytotoxic Agents
- EMA/PDCO Summary Report on the Review of the List of Granted Class Waivers
- SAHA Overcomes 5-FU Resistance in IFIT2-Depleted Oral Squamous Cell Carcinoma Cells
- Schedule-Dependent Synergism and Antagonism Between Methotrexate
- Oncology Agents Not Listed in Seer Book 8
- Selective Preservation of Pemetrexed
- Phase I Trial and Pharmacokinetic Study of Raltitrexed in Children with Recurrent Or Refractory Leukemia: a Pediatric Oncology Group Study